Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Vallon Pharmaceuticals, Inc., not GRI Bio, Inc. The report, dated July 27, 2022, states that the company issued a press release on July 28, 2022, announcing financial results for the quarter ended June 30, 2022, and providing a business update.
Financial Results and Liquidity
The filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, margins, debt, cash and equivalents, liquidity, or other financial metrics. It refers to an accompanying press release that is not included in the provided text.
Material Changes Versus Prior Period
The filing does not provide quantitative or qualitative details regarding changes from the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing states that a business update was provided, but the related commentary, guidance, risks, contingencies, and unusual items are not included in the supplied filing text.
The information was furnished under Item 2.02 and was not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other SEC filings.
Key Facts to Verify
- Verify the issuer identity: the supplied filing names Vallon Pharmaceuticals, Inc., while the request metadata identifies GRI Bio, Inc.
- Obtain and review the referenced press release for the quarter ended June 30, 2022, because the financial results and business update are absent from the provided text.
- Verify the exhibit reference: the filing body refers to Exhibit 99.1, while the exhibit list identifies Exhibit 10.1 as a press release dated May 9, 2022.
- Confirm the filing date discrepancy: the report identifies July 27, 2022 as the earliest event date, while the signature and described press release date are July 28, 2022.